Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Targeted Therapy 1Spinal Cord Neoplasms 1Oligodendroglioma 1Myeloproliferative Disorders 1Myeloid Malignancies 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 37Radiotherapy 20Bevacizumab 14Carboplatin 10Magnetic Resonance Spectroscopy 9Carmustine 9antineoplaston AS 2-1 8antineoplaston A10 8Irinotecan 8Filgrastim 7Cyclophosphamide 6Cisplatin 6Etoposide 5sargramostim 4Vincristine 4Thiotepa 4Surgical Procedures, Operative 4Specimen Handling 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Lomustine 4Everolimus 4Chemotherapy, Adjuvant 4trametinib 3aldesleukin 3Topotecan 3Thalidomide 3Tamoxifen 3Sunitinib 3Procarbazine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Astrocytoma × olutasidenib × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡